Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab Journal Article
| Authors: | Wistuba-Hamprecht, K.; Martens, A.; Haehnel, K.; Geukes Foppen, M.; Yuan, J.; Postow, M. A.; Wong, P.; Romano, E.; Khammari, A.; Dreno, B.; Capone, M.; Ascierto, P. A.; Demuth, I.; Steinhagen-Thiessen, E.; Larbi, A.; Schilling, B.; Schadendorf, D.; Wolchok, J. D.; Blank, C. U.; Pawelec, G.; Garbe, C.; Weide, B. |
| Article Title: | Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab |
| Abstract: | Human γδ T-cells possess regulatory and cytotoxic capabilities, and could potentially influence the efficacy of immunotherapies. We analysed the frequencies of peripheral γδ T-cells, including their most prominent subsets (Vδ1+ and Vδ2+ cells) and differentiation states in 109 melanoma patients and 109 healthy controls. We additionally analysed the impact of γδ T-cells on overall survival (OS) calculated from the first dose of ipilimumab in melanoma patients. Higher median frequencies of Vδ1+ cells and lower median frequencies of Vδ2+ cells were identified in patients compared to healthy subjects (Vδ1+: 30% versus 15%, Vδ2+: 39% versus 64%, both p < 0.001). Patients with higher frequencies of Vδ1+ cells (≥30%) had poorer OS (p = 0.043) and a Vδ1+ differentiation signature dominated by late-differentiated phenotypes. In contrast, higher frequencies of Vδ2+ cells (≥39%) were associated with longer survival (p = 0.031) independent of the M category or lactate dehydrogenase level. Patients with decreasing frequencies of Vδ2+ cells under ipilimumab treatment had worse OS and a lower rate of clinical benefit than patients without such decreases. Therefore, we suggest frequencies of both Vδ1+ and Vδ2+ cells as candidate biomarkers for outcome in melanoma patients following ipilimumab. Further studies are needed to validate these results and to clarify whether they represent prognostic associations or whether γδ T-cells are specifically and/or functionally linked to the mode of action of ipilimumab. © 2016 Elsevier Ltd |
| Keywords: | survival; ipilimumab; melanoma; immunotherapy; biomarker; γδ t-cells |
| Journal Title: | European Journal of Cancer |
| Volume: | 64 |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2016-09-01 |
| Start Page: | 116 |
| End Page: | 126 |
| Language: | English |
| DOI: | 10.1016/j.ejca.2016.06.001 |
| PROVIDER: | scopus |
| PUBMED: | 27400322 |
| PMCID: | PMC5201188 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 August 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work